Hepatitis B Topics HBV Treatment
AASLD 2017: REP 2139 Combination Therapy Leads to Functional Control of Hepatitis B Virus
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
A majority of chronic hepatitis B patients treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve "functional control" of hepatitis B virus (HBV), according to a late-breaking poster presentation at the 2017 AASLD Liver Meeting last month in Washington, DC.
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- Details
- Category: HBV Treatment Guidelines
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.
EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.
EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the EASL International Liver Congress last week in Amsterdam.
Web Design and Development by